Read Microsoft Word - Final+Program+schedule+as+of+June+2011_complete.doc text version

2011 GROVER CONFERENCE ON RISK FACTORS IN PULMONARY HYPERTENSION: GENDER, SEX HORMONES, OBESITY, NOVEL GENETIC INFLUENCES AND RISK FACTORS

COURSE SCHEDULE

Wednesday, September 7, 2011 12:00 pm - Arrivals 6.00 pm - Welcome Reception and Dinner Thursday, September 8, 2011 Session I (Part I): Genetic Risk Factors Chairs: Richard Trembath, Nicholas W. Morrell, Jim Loyd 6:55-7:55 am Breakfast 8:00 am Welcome and Introduction E. Kenneth Weir, MD, Minneapolis, MN (University of Minnesota)

8:10 am Update and Overview of Genetic Influences (Including update on New Genetic Studies vs. Association Studies). James E. Loyd, MD, Nashville, TN (Vanderbilt University Center for Lung Research) 8:45 am Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. K.E. Roberts, MD, Boston, MA (Tufts University Medical Center) 9:20 am Novel Loci Interacting Epistatically With Bone Morphogenetic Protein Receptor 2 Cause Familial Pulmonary Arterial Hypertension. David A. Greenberg, PhD, New York, NY (Columbia University) 9:55 am Break (10 min) 10:05 am Estelle Grover Lecture A Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated with Idiopathic Pulmonary Arterial Hypertension Jason X-J Yuan, MD, PhD, San Diego, California (University of California San Diego) 10:55 am microRNAs-control of Essential Genes: Recent Implications. William T. Gerthoffer, PhD, Mobile, Alabama (University of South Alabama) 11:30 am Risk Factors in PPHN David N. Cornfield, MD, Palo Alto, CA (Stanford University) 12:05 pm The Hypoxic Pulmonary Hypertensive Gene John H. Newman, MD, Nashville, TN (Vanderbilt University School of Medicine) 12:40 pm Lunch Session I (Part II) Obesity as a Risk Factor Chairs: Norbert Voelkel, Matt Thomas, Novartis, Troy Stevens 3:00 pm Metabolic syndrome and PPARgamma Antonio Vidal-Puig, MD, Cambridge, UK (University of Cambridge) 3:45 pm Obesity and Thyroid Disease in Women with Severe Pulmonary Hypertension Norbert Voelkel, MD, Richmond, VA (Virginia Commonwealth University Medical Center)

4:20 pm Etiologies and Comorbidities in pulmonary hypertension: Insight from the REVEAL Registry David A. Badesch, MD, Aurora, CO (University of Colorado Denver) 4:55 pm Exercise Capacity, COPD and Pulmonary Hypertension Matthew Thomas, PhD, UK (Novartis Institutes for BioMedical Research) 6:30 pm Dinner Friday, September 9, 2011 Session II (Part I). Endogenous factors and PAH Chairs: Sami Said, Ken Weir 6:55-7:55 am Breakfast 8:05 am Terry Wagner Lecture Vasoactive Intestinal Peptide Gene is a Key Modulator of Pulmonary Vascular Remodeling and Inflammation Sami I. Said, MD, Stony Brook, NY (SUNY at Stony Brook) . 8:55 am C-type natriuretic peptides in the human circulation and relation to cardiac function A. Mark Richards, MD, PhD, Otago, New Zealand (University of Otago, New Zealand) 9:30 am Adiponectin Deficiency: A Model of Pulmonary Hypertension Associated with Pulmonary Vascular Disease Kenneth Walsh, PhD, Boston, MA (Boston University School of Medicine) 10:05 am Break (10 min) 10:15 am Apelin and Pulmonary Hypertension Charlotte Andersen, Copenhagen, Denmark (Pfizer Europe) . 10:50 am Adiponectin and Pulmonary Vascular Remodeling Benjamin D. Medoff, MD, Boston, MA (Massachusetts General Hospital) . 12:00 pm Lunch Session III (Part I). Estrogen metabolism and disease penetrance Chairs: John West Karen Fagan, Mark Gillespie 4:00 pm Alterations in estrogen metabolism: Implications for higher penetrance of FPAH in females Eric D. Austin, MD, Nashville, TN (Vanderbilt University) . 4:35 pm Young Investigator Award Talk chosen from submitted abstract TBD 5:00 pm Gene Expression and CYP1B1 in BMPR2 Mutation Carriers with and without Evidence of Pulmonary Arterial Hypertension suggests Pathways Relevant to Disease Penetrance. James D. West, PhD, Nashville, TN (Vanderbilt University School of Medicine) 5:35 pm Young Investigator Award. Talk chosen from submitted abstract 6:30 pm Dinner

Saturday, September 10, 2011 Session III (Part II) Epigenetics Chairs: Stephen Archer, Ivan McMurtry, Mandy MacLean 6:55-7:55 Breakfast 8:05 am Epigenetics and Cardiovascular Disease Virginia H. Huxley, PhD, Columbia, MO (National Center for Gender Physiology, University of Missouri-Columbia) 8:50 am John Reeves Lecture Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in PAH Stephen L. Archer, MD, Chicago, IL (University of Chicago)

9:35 am Break (10 min) Session III (Part III) Sex Hormones and PAH 9:45 AM Estradiol Metabolites and Progestins in Experimental PAH Stevan P. Tofovic, DSc, MD, Pittsburgh, PA (University of Pittsburgh School of Medicine) 10:20 am Dehydroepiandrosterone and Experimental PAH Masahiko Oka, MD, PhD, Mobile, AL (University of South Alabama) 10:55 am Serotonin, Estrogens and PAH Mandy R. MacLean, PhD, Glasgow, UK (University of Glasgow) 11:30 am PPHN, serotonin as risk factor Cassidy Delaney, MD, Aurora, Colorado (University of Colorado Hospital) 12:30 pm Lunch Session IV Risk Factors in Pulmonary Hypertension: Gender, Sex Hormones, Obesity, Novel Genetic Influences, and Novel Risk Factors Facilitators/Chairs: Karen Fagan, Larissa Shimoda, 4:00 pm Abstract/Poster Review 7:00 pm Dinner Sunday 11th September Session V 2011 Risk Factors and Responsiveness to Current and Emerging Therapies Chairs: John Westwick, Kurt Stenmark, Jason Yuan 7:00-8:00 am Breakfast 8:00 am Biomarkers in PAH ­ can we predict responsiveness to specific therapies? Martin Wilkins, MD, London UK (Imperial College) 8:35 am Prostacyclin-Mediated Changes to Inflammation in PAH Kurt R. Stenmark, MD, Denver, CO (University of Colorado Denver)

9:05 am The effect of Sildenafil Treatment on TRPC Channels Jian Wang, PhD, Baltimore, MD (Johns Hopkins University) 9:40 am Break (10 min) 9:50 am Gender Differences in Vascular Reactivity to Endothelin-1 Rita C. Tostes, PhD, Sao Paulo, Brazil (University of Sao Paulo) 10:25 am The Role of Medical Therapy in Non-PAH PH Marius M. Hoeper, MD, Hannover, Germany (Hannover Medical School) 11:00 am Vascular Progenitors in PAH ­ Biomarkers, Targets or Therapy? Nicholas W. Morrell, MD, Cambridge, UK (Cambridge University) 11:35 am Risk Factors and Responsiveness to Therapies in the Modern Era of PAH Treatment Oliver Sitbon, MD, Paris, France (Hopital Antoine Beclere) 12:10 pm Closing summary (10 min) Mandy MacLean and Karen Fagan 12:30 Lunch

Conference adjourns after lunch

Information

Microsoft Word - Final+Program+schedule+as+of+June+2011_complete.doc

4 pages

Find more like this

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

1044156


You might also be interested in

BETA
D:\_abs\ers2006\E.DVI
Think Tank on Enhancing Obesity Research at the National Heart, Lung, and Blood Institute
C:\_abs\ers2009\E.DVI